(DSFIR) DSM-Firmenich - Ratings and Ratios
Nutrition, Health, Beauty, Flavors, Vitamins, Enzymes, Proteins
DSFIR EPS (Earnings per Share)
DSFIR Revenue
Description: DSFIR DSM-Firmenich
DSM-Firmenich AG is a leading global player in the nutrition, health, and beauty industry, operating across multiple regions including Europe, North America, Latin America, and Asia. The company is structured into four key segments: Perfumery & Beauty, Taste, Texture & Health, Health, Nutrition & Care, and Animal Nutrition & Health, offering a diverse range of products and solutions.
The companys product portfolio includes scents, flavors, natural extracts, nutritional ingredients, and animal nutrition solutions, catering to various markets such as food and beverages, dietary supplements, pharmaceuticals, and animal proteins. DSM-Firmenich AG also provides expert services in regulatory affairs and nutrition, as well as data-driven precision services for animal nutrition.
From a financial perspective, DSM-Firmenich AG has a significant market presence with a market capitalization of 23.366 billion EUR. The companys current valuation metrics indicate a P/E ratio of 95.04 and a forward P/E of 21.19, suggesting a potential for earnings growth. However, the current Return on Equity (RoE) is -0.85, indicating a need for improvement in profitability. To further analyze the companys performance, other key performance indicators (KPIs) such as Revenue Growth, Gross Margin, and Operating Margin should be examined.
Some additional KPIs that could provide insight into DSM-Firmenich AGs performance include: Debt-to-Equity ratio, Interest Coverage ratio, and Return on Assets (RoA). These metrics can help assess the companys capital structure, ability to meet interest payments, and asset utilization efficiency. Furthermore, analyzing the companys dividend yield, payout ratio, and earnings per share (EPS) growth can provide a more comprehensive understanding of its investment potential.
DSFIR Stock Overview
| Market Cap in USD | 25,556m |
| Sub-Industry | Personal Care Products |
| IPO / Inception |
DSFIR Stock Ratings
| Growth Rating | -52.4% |
| Fundamental | 52.9% |
| Dividend Rating | 56.4% |
| Return 12m vs S&P 500 | -40.5% |
| Analyst Rating | - |
DSFIR Dividends
| Dividend Yield 12m | 2.99% |
| Yield on Cost 5y | 2.43% |
| Annual Growth 5y | 25.00% |
| Payout Consistency | 100.0% |
| Payout Ratio | 63.8% |
DSFIR Growth Ratios
| Growth Correlation 3m | -92.4% |
| Growth Correlation 12m | -82.4% |
| Growth Correlation 5y | 12.1% |
| CAGR 5y | -10.90% |
| CAGR/Max DD 5y | -0.30 |
| Sharpe Ratio 12m | -2.60 |
| Alpha | -36.88 |
| Beta | 0.318 |
| Volatility | 22.41% |
| Current Volume | 444k |
| Average Volume 20d | 418.1k |
| Stop Loss | 80.9 (-3.1%) |
| Signal | -1.07 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (-190.0m TTM) > 0 and > 6% of Revenue (6% = 747.3m TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA 1.00pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 35.64% (prev 39.39%; Δ -3.75pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 1.45b > Net Income -190.0m (YES >=105%, WARN >=100%) |
| Net Debt (2.61b) to EBITDA (978.5m) ratio: 2.67 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.02 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (265.0m) change vs 12m ago -0.30% (target <= -2.0% for YES) |
| Gross Margin 27.19% (prev 33.07%; Δ -5.88pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 36.62% (prev 32.04%; Δ 4.58pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' 1.89
| (A) 0.13 = (Total Current Assets 8.80b - Total Current Liabilities 4.36b) / Total Assets 33.75b |
| (B) 0.31 = Retained Earnings (Balance) 10.57b / Total Assets 33.75b |
| (C) 0.00 = EBIT TTM 31.0m / Avg Total Assets 34.01b |
| (D) 0.0 = Book Value of Equity 0.0 / Total Liabilities 11.05b |
| Total Rating: 1.89 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 52.94
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 2.82% = 1.41 |
| 3. FCF Margin 6.05% = 1.51 |
| 4. Debt/Equity 0.33 = 2.45 |
| 5. Debt/Ebitda 7.69 = -2.50 |
| 6. ROIC - WACC -5.42% = -6.78 |
| 7. RoE -0.85% = -0.14 |
| 8. Rev. Trend 37.08% = 1.85 |
| 9. Rev. CAGR 11.09% = 1.39 |
| 10. EPS Trend 55.10% = 1.38 |
| 11. EPS CAGR 23.81% = 2.38 |
What is the price of DSFIR shares?
Over the past week, the price has changed by -1.70%, over one month by -2.91%, over three months by -14.99% and over the past year by -30.38%.
Is DSM-Firmenich a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DSFIR is around 70.74 EUR . This means that DSFIR is currently overvalued and has a potential downside of -15.28%.
Is DSFIR a buy, sell or hold?
What are the forecasts/targets for the DSFIR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 117.8 | 41% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 76.8 | -8.1% |
DSFIR Fundamental Data Overview
Market Cap EUR = 21.94b (21.94b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 2.72b EUR (Cash And Short Term Investments, last quarter)
P/E Trailing = 31.0221
P/E Forward = 19.6078
P/S = 1.6863
P/B = 1.0078
P/EG = 0.4853
Beta = 1.035
Revenue TTM = 12.46b EUR
EBIT TTM = 31.0m EUR
EBITDA TTM = 978.5m EUR
Long Term Debt = 6.69b EUR (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 836.0m EUR (from shortTermDebt, last quarter)
Debt = 7.53b EUR (Calculated: Short Term 836.0m + Long Term 6.69b)
Net Debt = 2.61b EUR (from netDebt column, last quarter)
Enterprise Value = 26.75b EUR (21.94b + Debt 7.53b - CCE 2.72b)
Interest Coverage Ratio = unknown (Ebit TTM 31.0m / Interest Expense TTM 0.0)
FCF Yield = 2.82% (FCF TTM 753.0m / Enterprise Value 26.75b)
FCF Margin = 6.05% (FCF TTM 753.0m / Revenue TTM 12.46b)
Net Margin = -1.53% (Net Income TTM -190.0m / Revenue TTM 12.46b)
Gross Margin = 27.19% ((Revenue TTM 12.46b - Cost of Revenue TTM 9.07b) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 26.75b / Book Value Of Equity 0.0)
Interest Expense / Debt = 1.02% (Interest Expense 77.0m / Debt 7.53b)
Taxrate = 34.43% (from yearly Income Tax Expense: 147.0m / 427.0m)
NOPAT = 20.3m (EBIT 31.0m * (1 - 34.43%))
Current Ratio = 2.02 (Total Current Assets 8.80b / Total Current Liabilities 4.36b)
Debt / Equity = 0.33 (Debt 7.53b / last Quarter total Stockholder Equity 22.51b)
Debt / EBITDA = 7.69 (Net Debt 2.61b / EBITDA 978.5m)
Debt / FCF = 9.99 (Debt 7.53b / FCF TTM 753.0m)
Total Stockholder Equity = 22.41b (last 4 quarters mean)
RoA = -0.56% (Net Income -190.0m, Total Assets 33.75b )
RoE = -0.85% (Net Income TTM -190.0m / Total Stockholder Equity 22.41b)
RoCE = 0.11% (Ebit 31.0m / (Equity 22.41b + L.T.Debt 6.69b))
RoIC = 0.10% (NOPAT 20.3m / Invested Capital 19.98b)
WACC = 5.52% (E(21.94b)/V(29.47b) * Re(7.19%)) + (D(7.53b)/V(29.47b) * Rd(1.02%) * (1-Tc(0.34)))
Shares Correlation 5-Years: 90.0 | Cagr: 11.44%
Discount Rate = 7.19% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 76.43% ; FCFE base≈620.8m ; Y1≈551.6m ; Y5≈462.1m
Fair Price DCF = 32.42 (DCF Value 8.37b / Shares Outstanding 258.3m; 5y FCF grow -13.73% → 3.0% )
Revenue Correlation: 37.08 | Revenue CAGR: 11.09%
Rev Growth-of-Growth: -2.76
EPS Correlation: 55.10 | EPS CAGR: 23.81%
EPS Growth-of-Growth: 211.8